Topics:

Abbott said to be looking at buying Bausch + Lomb

Sources say it might buy the whole deal while others say it might only want parts
Tools

Having just spun off the drug development part of its business, could Abbott Laboratories ($ABT) really be considering a $10 billion deal to buy eye-care company Bausch + Lomb?

Sources tell Bloomberg that is the case. They also say Johnson & Johnson ($JNJ) and Sanofi ($SNY) are kicking the tires on the company, which private equity firm Warburg Pincus is looking to unload. Abbott and Johnson & Johnson are new names to be floated by sources, perhaps to keep interest warm for a deal. Last month The Wall Street Journal was reporting interest from Sanofi and Merck ($MRK). Of course no one from any of the companies has any for-the-record comment.

The $10 billion is what Warburg Pincus would like to get, not necessarily what it would sell for. That would pencil out to a 200% gain on its investment. It took Bausch + Lomb private in 2007 in a deal valued at $4.6 billion, including debt. The contact lens and eye drug company reportedly has seen its earnings grow to just under $700 million a year from about $400 million at the time. 

Bausch + Lomb first brings to the mind's eye contact lenses and solutions, but it has developed its prescription drug business in recent years. That includes the $500 million acquisition of eye drug company ISTA, which it completed in June. The deal added ISTA's product pipeline to its own, as well as products such as Bromday, a drop for cataract surgery patients.

Sources says Warburg Pincus likes suitors such as Abbott that might be interested in the whole enchilada, as opposed to companies--Sanofi perhaps--that might be interested in picking up just pieces of Bausch + Lomb. There are tax benefits, and so more to be made, from selling it intact, sources say. Warburg Pincus earlier said it would spin the company off into a publicly traded business and is making sure everyone knows it can still go that route if potential bidders are not thinking in big enough numbers. 

- read the Bloomberg story

Related Articles:
Sanofi, Merck, others said to be eyeing Bausch buyout
AbbVie is pharma's first birth of the new year
ISTA's hard-to-get stance yields $500M Bausch + Lomb bid
Bausch + Lomb eyes pharma ops expansion